Exploring the Potential of the SGLT 2 Inhibitor Dapagli fl ozin in Type 1 Diabetes : A Randomized , Double-Blind , Placebo-Controlled Pilot Study

RESEARCH DESIGN AND METHODS A 2-week, dose-ranging, randomized, double-blind, placebo-controlled proof-ofconcept study randomly assigned 70 adultswith type 1 diabetes (HbA1c 7–10%),who were receiving treatment with stable doses of insulin, to one of four dapagliflozin doses (1, 2.5, 5, or 10mg) or placebo. The insulin dosewas not proactively reduced at randomization but could be adjusted for safety reasons. The primary objective was to assess short-term safety; secondary objectives included pharmacokinetic, pharmacodynamic, and efficacy parameters.

[1]  V. Woo,et al.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years , 2014, Diabetes, obesity & metabolism.

[2]  R. Beck,et al.  Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. , 2013, The Journal of clinical endocrinology and metabolism.

[3]  V. Woo,et al.  Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.

[4]  F. LaCreta,et al.  Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus , 2011, Diabetes, obesity & metabolism.

[5]  M. Pfister,et al.  Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus , 2009, Clinical pharmacology and therapeutics.

[6]  D. Russell-Jones,et al.  Insulin‐associated weight gain in diabetes – causes, effects and coping strategies , 2007, Diabetes, obesity & metabolism.

[7]  A. Rigby,et al.  Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes , 2007, Diabetes Care.

[8]  C. Mogensen.  Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. , 1971, Scandinavian journal of clinical and laboratory investigation.